Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002194
UniProt IDP61925
Primary gene name(s)PKIA
Synonym gene name(s)PRKACN1
Protein namecAMP-dependent protein kinase inhibitor alpha
Protein functionExtremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains.
Subcellular locationunknown
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P61925
Gene Ontology
(Biological Process)
Complete annatation
negative regulation of cAMP-dependent protein kinase activity [GO:2000480];
negative regulation of protein import into nucleus [GO:0042308];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
regulation of G2/M transition of mitotic cell cycle [GO:0010389]
Gene Ontology
(Molecular Function)
Complete annatation
cAMP-dependent protein kinase inhibitor activity [GO:0004862];
protein kinase A catalytic subunit binding [GO:0034236]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
nucleus [GO:0005634]
Protein-protein interaction111556
Phylogenetic treeP61925
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      Negatively associated
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.352225006193790.03173305171472720.0682185929887845
AZA vs. DISU0.08339752951901210.7428732307064850.976008954784031
AZA vs. IL7-0.3037490396410390.1235278575273150.889601240568185
AZA vs. SAHA0.4498400344105640.06704204455448970.318649463061873
DISU vs. CD3-1.282678597639790.0435171265179650.0964530458949867
DISU vs. IL7-0.3955946370693850.1203944507518970.454190777048258
DISU vs. SAHA0.3669736615394770.2093081970432210.58319168749092
DMSO vs. AZA-0.04697274752947010.7845382048873371
DMSO vs. CD3-1.414367586962790.02275955001572060.0498288941995104
DMSO vs. DISU-0.1331540558174440.5871339600101540.934701463289767
DMSO vs. IL7-0.2494127093750340.1713854319622580.681879201707603
DMSO vs. SAHA0.4898653717075390.0390801147971320.218868974398951
HIV vs. Mock in Activation-0.2189905972901980.8642961944341650.999983755607037
HIV vs. Mock in Latency-0.07611956458665960.6492372648029880.999834320637052
IL7 vs. CD3-1.646034961931580.0109485236232990.0321752966609448
SAHA vs. CD3-0.9285386637641840.1341905606576450.220456965999206
SAHA vs. IL70.7484964083919110.002459910724993410.0229601822096289
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
0.3605 0.02684

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
-1.3 0.032735555 -1.4 0.003601807 -1.9 3.97E-06
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -1.09061 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB06959 (1S)-2-(1H-INDOL-3-YL)-1-{[(5-ISOQUINOLIN-6-YLPYRIDIN-3-YL)OXY]METHYL}ETHYLAMINE experimental unknown unknown
DB07107 (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE experimental unknown unknown
DB07204 (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE experimental unknown unknown
DB07583 (4R,2S)-5&,39;-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE experimental unknown unknown
DB07854 N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE experimental unknown unknown
DB07855 (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE experimental unknown unknown
DB07856 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE experimental unknown unknown
DB07857 (2R)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB07858 (2S)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB07859 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE experimental unknown unknown
DB07860 (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE experimental unknown unknown
DB07876 (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE experimental unknown unknown
DB04707 HYDROXYFASUDIL experimental unknown unknown
DB07947 ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE experimental unknown unknown
DB07995 N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE experimental unknown unknown
DB07996 5-(2-methylpiperazine-1-sulfonyl)isoquinoline experimental unknown unknown
DB07997 N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE experimental unknown unknown
DB08070 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE experimental unknown unknown
DB08073 (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE experimental unknown unknown
DB08113 3-pyridin-4-yl-1H-indazole experimental unknown unknown
DB08114 5-benzyl-1,3-thiazol-2-amine experimental unknown unknown
DB08148 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine experimental unknown unknown
DB08149 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine experimental unknown unknown
DB08150 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium experimental unknown unknown
DB08162 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE experimental unknown unknown
DB08231 MYRISTIC ACID experimental unknown unknown
DB08568 (2S)-1-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}-3-PHENYLPROPAN-2-AMINE experimental unknown unknown
DB08569 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE experimental unknown unknown
DB03374 3,5-Diiodotyrosine experimental unknown unknown
DB08756 (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1CMK X-ray 2.9Å I=6-27.
1JLU X-ray 2.2Å S=6-25.
1Q8T X-ray 2.0Å B=6-25.
1VEB X-ray 2.8Å B=6-25.
1XH4 X-ray 2.4Å B=6-25.
1XH5 X-ray 2.0Å B=6-25.
1XH6 X-ray 1.9Å B=6-25.
1XH7 X-ray 2.4Å B=6-25.
1XH8 X-ray 1.6Å B=6-25.
1XH9 X-ray 1.6Å B=6-25.
1XHA X-ray 2.4Å B=6-25.
1YDR X-ray 2.2Å I=6-25.
2C1A X-ray 1.9Å I=6-25.
2C1B X-ray 2.0Å I=6-25.
2F7E X-ray 2.0Å I=6-25.
2GNI X-ray 2.2Å I=6-25.
2JDS X-ray 2.0Å I=6-25.
2JDT X-ray 2.1Å I=6-25.
2JDV X-ray 2.0Å I=6-25.
2L1L NMR - A=30-54.
2UVX X-ray 2.0Å I=6-25.
2UVY X-ray 1.9Å I=6-25.
2UVZ X-ray 1.9Å I=6-25.
2UW0 X-ray 2.0Å I=6-25.
2UW3 X-ray 2.1Å I=6-25.
2UW4 X-ray 2.0Å I=6-25.
2UW5 X-ray 2.1Å I=6-25.
2UW6 X-ray 2.2Å I=6-25.
2UW7 X-ray 2.1Å I=6-25.
2UW8 X-ray 2.0Å I=6-25.
2VNW X-ray 2.0Å I=6-25.
2VNY X-ray 1.9Å I=6-25.
2VO0 X-ray 1.9Å I=6-25.
2VO3 X-ray 1.9Å I=6-25.
2VO6 X-ray 1.9Å I=6-25.
2VO7 X-ray 1.9Å I=6-25.
3AMA X-ray 1.7Å B=6-25.
3AMB X-ray 2.2Å B=6-25.
3L9L X-ray 2.0Å C/D=6-25.
3L9M X-ray 1.9Å C/D=6-25.
3L9N X-ray 2.0Å C=6-25.
3MVJ X-ray 2.4Å I/J/K=6-25.
3NX8 X-ray 2.0Å B=6-25.
3OOG X-ray 2.0Å B=6-25.
3OVV X-ray 1.5Å B=6-25.
3OWP X-ray 1.8Å B=6-25.
3OXT X-ray 2.2Å B=6-25.
3P0M X-ray 2.0Å B=6-25.
3POO X-ray 1.6Å B=6-25.
3VQH X-ray 1.9Å B=6-25.
3WYG X-ray 2.1Å D=1-76.
3X2U X-ray 2.4Å S=6-25.
3X2V X-ray 1.7Å S=6-25.
3X2W X-ray 1.7Å S=6-25.
4AXA X-ray 1.9Å I=6-25.
4IAC X-ray 2.1Å S=6-25.
4IAD X-ray 1.9Å S=6-25.
4IAF X-ray 2.2Å S=6-25.
4IAI X-ray 1.5Å S=6-25.
4IAK X-ray 1.6Å S=6-25.
4IAY X-ray 2.0Å S=6-25.
4IAZ X-ray 1.8Å S=6-25.
4IB0 X-ray 1.8Å S=6-25.
4IB1 X-ray 1.6Å S=6-25.
4IB3 X-ray 2.2Å S=6-25.
4IE9 X-ray 1.9Å I=6-25.
4IJ9 X-ray 2.5Å I=6-25.
4O21 X-ray 1.9Å S=6-25.
4O22 X-ray 1.7Å S=6-25.
4UJ1 X-ray 1.7Å B=6-25.
4UJ2 X-ray 2.0Å B=6-25.
4UJ9 X-ray 1.8Å B=6-25.
4UJA X-ray 1.9Å B=6-25.
4UJB X-ray 1.9Å B=6-25.
4WB5 X-ray 1.6Å I=6-25.
4WB6 X-ray 2.1Å I/J=6-25.
4WB7 X-ray 1.9Å I/J=6-25.
4WB8 X-ray 1.5Å I=6-25.
4Z83 X-ray 1.8Å I=6-25.
4Z84 X-ray 1.5Å I=6-25.
5BX6 X-ray 1.8Å B=6-25.
5BX7 X-ray 1.8Å B=6-25.
5DH9 X-ray 2.5Å D=36-46.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa05034 Alcoholism - Homo sapiens (human)
Menu